MARKET

PHAT

PHAT

Phathom Pharmaceuticals, Inc.
NASDAQ
5.45
+0.12
+2.16%
After Hours: 5.51 +0.07 +1.19% 19:36 11/10 EST
OPEN
5.27
PREV CLOSE
5.33
HIGH
5.55
LOW
5.15
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
18.31
52 WEEK LOW
5.02
MARKET CAP
442.63M
P/E (TTM)
-5.2854
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHAT last week (1102-1106)?
Weekly Report · 1d ago
Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx
Benzinga · 11/03 13:01
Leerink Partners Sticks to Their Hold Rating for Phathom Pharmaceuticals (PHAT)
TipRanks · 11/02 16:42
Weekly Report: what happened at PHAT last week (1026-1030)?
Weekly Report · 11/02 09:42
Phathom Pharmaceuticals (PHAT) Stock Price Drops After Q3 Earnings Growth
Simply Wall St · 10/30 23:35
Phathom Pharmaceuticals (PHAT) Receives a Buy from H.C. Wainwright
TipRanks · 10/30 10:37
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Alnylam Pharma (ALNY) and Illumina (ILMN)
TipRanks · 10/30 09:50
Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
NASDAQ · 10/29 18:55
More
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.

Webull offers Phathom Pharmaceuticals Inc stock information, including NASDAQ: PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.